Novo Nordisk Long-Term Investments 2010-2024 | NVO

Novo Nordisk long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • Novo Nordisk long-term investments for the quarter ending September 30, 2024 were $0.302B, a 40.49% increase year-over-year.
  • Novo Nordisk long-term investments for 2023 were $0.241B, a 26.98% increase from 2022.
  • Novo Nordisk long-term investments for 2022 were $0.19B, a 17.05% decline from 2021.
  • Novo Nordisk long-term investments for 2021 were $0.229B, a 9.19% decline from 2020.
Novo Nordisk Annual Long-Term Investments
(Millions of US $)
2023 $241
2022 $190
2021 $229
2020 $252
2019 $271
2018 $271
2017 $268
2016 $326
2015 $320
2014 $153
2013 $98
2012 $39
2011 $7
2010 $8
2009 $33
Novo Nordisk Quarterly Long-Term Investments
(Millions of US $)
2024-09-30 $302
2024-06-30 $239
2024-03-31 $240
2023-12-31 $241
2023-09-30 $215
2023-06-30 $216
2023-03-31 $175
2022-12-31 $190
2022-09-30 $168
2022-06-30 $178
2022-03-31 $193
2021-12-31 $229
2021-09-30 $282
2021-06-30 $298
2021-03-31 $284
2020-12-31 $252
2020-09-30 $256
2020-06-30 $273
2020-03-31 $255
2019-12-31 $271
2019-09-30 $307
2019-06-30 $316
2019-03-31 $260
2018-12-31 $271
2018-09-30 $241
2018-06-30 $244
2018-03-31 $258
2017-12-31 $268
2017-09-30 $350
2017-06-30 $296
2017-03-31 $293
2016-12-31 $326
2016-09-30 $300
2016-06-30 $296
2016-03-31 $290
2015-12-31 $320
2015-09-30 $310
2015-06-30 $329
2015-03-31 $279
2014-12-31 $153
2014-09-30 $147
2014-06-30 $142
2014-03-31 $138
2013-12-31 $98
2013-09-30 $36
2013-06-30 $35
2013-03-31 $43
2012-12-31 $39
2012-09-30 $44
2012-06-30 $42
2012-03-31 $53
2011-12-31 $7
2011-09-30 $8
2011-06-30 $8
2011-03-31 $8
2010-12-31 $8
2010-09-30 $47
2010-06-30 $48
2010-03-31 $52
2009-12-31 $33
2009-09-30 $31
2009-06-30 $31
2009-03-31 $28
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51